|
|
|
|
Office Locations:
|
23 King Street
London, SW1Y 6QY
United Kingdom
Phone: 44-20-7747-5040
| |
|
|
|
|
|
|
Communications & Networking
Consumer Products & Services
Energy & Clean Tech
Financial Services
Life Sciences & Healthcare
Media & Digital Media
Real Estate & Construction
Transportation & Distribution
|
|
|
|
Incorporated in 1974, Temasek is an investment company based in Singapore. Supported by 11 offices globally, Temasek owns a S$242 billion portfolio as at 31 March 2016, mainly in Singapore and Asia. Temasek's investment themes center on: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions. Its portfolio covers a broad spectrum of industries: financial services; telecommunications, media and technology; transportation and industrials; life sciences, consumer and real estate; as well as energy and resources. Temasek is governed by the provisions of the Singapore Company Act.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Benoit Valentin | |
| |
Senior Managing Director | |
| Gregory Curl | |
| |
President | |
| Ho Ching | |
| |
Executive Director & CEO | |
| Lee Theng Kiat | |
| |
Executive Director & CEO | |
| Luigi Feola | |
| |
Senior Managing Director | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
01/04/2019
|
PEAR Therapeutics
|
MA
|
$64,000,000
|
Series C
|
12/13/2018
|
Bowery Farming
|
NY
|
$90,000,000
|
|
10/02/2018
|
Pivot Bio
|
CA
|
$70,000,000
|
Series B
|
08/28/2018
|
Puls
|
CA
|
$50,000,000
|
Series C
|
08/14/2018
|
Orchard Therapeutics
|
MA
|
$150,000,000
|
Series C
|
08/09/2018
|
Akili Interactive
|
|
$13,000,000
|
Series C
|
07/29/2018
|
Flywire
|
MA
|
$100,000,000
|
Series D
|
07/27/2018
|
ClassPass
|
NY
|
$85,000,000
|
Series D
|
06/11/2018
|
Claroty
|
NY
|
$60,000,000
|
Series B
|
05/23/2018
|
Iora Health
|
MA
|
$100,000,000
|
Series E
|
05/09/2018
|
Akili Interactive Labs
|
MA
|
$55,000,000
|
Series C
|
04/03/2018
|
Impossible Foods
|
CA
|
$114,000,000
|
|
03/05/2018
|
C2FO
|
KS
|
$100,000,000
|
|
03/01/2018
|
Perfect Day
|
CA
|
$24,700,000
|
Series A
|
02/28/2018
|
Viela Bio
|
MD
|
$250,000,000
|
Series A
|
02/17/2018
|
Harry's
|
NY
|
$112,000,000
|
Series D
|
01/25/2018
|
Stem
|
CA
|
$80,000,000
|
Series D
|
|
|
|
|
|
|
|
